Cover Image
市場調查報告書

中國的Imatinib市場分析

Investigation Report on China Imatinib Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 297270
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Imatinib市場分析 Investigation Report on China Imatinib Market, 2009-2018
出版日期: 2014年03月04日 內容資訊: 英文 40 Pages
簡介

慢性骨髓性白血病(CML)的發病率,依地區而不同。全球發病率約100萬分之10,不過中國是100萬分之4。中國CML佔白血病約20%,佔慢性白血病的95%。CML的患者從年輕人到老年人都有,隨著老齡化發病率也增加了。Imatinib是Novartis開發的CML、費城染色體陽性急性淋巴性白血病(Ph+ALL),或胃腸道基質腫瘤(GIST)之形成原因的遺傳基因異常產生的只助長遺傳基因產物的疾病特異性的分子標靶治療藥。

本報告提供中國的Imatinib市場相關調查分析、主要廠商的市場佔有率、醫院市場上的銷售價格、主要製造商簡介、醫院市場上的市場佔有率(各劑型)、CML的發病率、學名藥的製造計劃、市場預測等,為您概述為以下內容。

第1章 Imatinib的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Imatinib的市場概要

  • 專利狀況
  • 主要製造商
  • 市場規模

第3章 中國的Imatinib的銷售額分析

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的Imatinib的主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售量

第5章 中國的Imatinib(各劑型)的市場規模分析

  • 市場佔有率:各銷售額、劑型
  • 市場佔有率:各銷售量、劑型

第6章 中國的醫院市場上Imatinib的標準價格

  • Novartis
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Hansoh Pharmaceutical

第7章 中國的Imatinib市場上主要製造商

  • Novartis
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Hansoh Pharmaceutical

第8章 中國的Imatinib市場預測

  • CML的發病率預測
  • 學名藥的製造計劃
  • 市場規模的預測
  • 競爭格局的預測

圖表

目錄
Product Code: 1403122

Incidence of chronic myelogenous leukemia (CML) varies in the world. The global incidence is about 10/1,000,000 while in China it is 4/1,000,000. CML takes up about 20% of leukaemia in China and 95% of chronic leukemia. CML patients vary from the very young to the very old, and the incidence increases as people grow old.

CML treatment went through a long period of development. Interferon used to be main medication before imatinib. It was initially used in CML treatment in 1980 and became the first genetically effective drug to treat chronic phase CML-CP since 1990. About 20% to 30% patients get cytogenetic remission and live longer using interferon. However, interferon is toxic because of too many unbearable side effects.

Imatinib is originally developed by Novartis with the trade name "Gleevec". It was approved to the U.S.A. to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) blastic phase, accelerated phase or patients in chronic phase after α-interferon failure. In November 2001 it was approved in Europe and to Chinese market in April 2002. Average survival time of CML patients used to be 3 to 6 years before imatinib was developed. Due to its revolutionary treatment, imatinib prolongs 85% to 90% CML patients' life by 10 years. With much less side effects, imatinib is significantly safer than interferon. As a result, it became a first-line drug in CML treatment soon.

In 2002 imatinib gained accelerated approval from FDA to be the first-line drug in advanced or metastatic gastrointestinal stromal tumors (GIST) treatment. As a first-line drug in clinical treatment, the sales revenue of imatinib exceeded USD 1 billion in 2003 and it is still increasing rapidly.

Imatinib acquired its first indication approval in 2001 and has since then acquired 10 indication approvals. Increasing number of indications is also one of the main factors making imatinib a blockbuster drug.

Imatinib was approved to China in 2002 to treat CML and GIST. Its market size keeps increasing after its launch. According to CRI's investigation on sample hospital market, the CAGR of its sales revenue exceeded 40% from 2005 to 2012. It is estimated that growth of original drugs will slow down because of launched generic drugs.

The huge success of targeted antitumor drugs in the market depends greatly on high treatment cost. In China, the monthly treatment cost of imatinib is over CNY 20 thousand. Compared with traditional antitumor drugs, fewer patients are needed to make it a blockbuster drug since they need to take it for a long time.

As an orphan drug approved to the market, imatinib becomes a blockbuster drug mainly due to the successful marketing strategy. Considered as a specific drug to treat rare diseases (CML and GIST), Gleevec makes a marketing strategy to launch drug donation charity program through negotiation with medicare institutes. The program allows patients to take the drug for free after the donation so as to increase patients' dependence on the drug. This gesture has not only solved patients' problems but also brought excellent reputation for Gleevec, making its global sales revenue surge.

Patent of imatinib compound in China expired in April 2013 while that of imatinib in crystal form expires in 2018. In July 2013, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Hansoh Pharmaceutical from China were approved to produce imatinib generic drugs. Since the generic drug is much cheaper than the original one, market share of imatinib in China is predicted to increase greatly in the future.

Through this report, the readers can acquire the following information:

  • Market Share of Major Imatinib Manufacturers in Sample Hospitals in China
  • Sales price of Imatinib in Hospital Market in China
  • Share of Imatinib in Different Dosage Forms in China Hospital Market
  • Incidence of CML in China
  • Manufacturing Schedule of Imatinib Generic Drug
  • Prospect of China Imatinib Market

The following enterprises and people are recommended to purchase this report:

  • Monoclonal Antibody APIs and Finished Product Manufacturers
  • Medical Institutions
  • Investors/Research Institutes Focusing on Imatinib Market

Table of Contents

1. Relevant Concepts of Imatinib

  • 1.1. Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Imatinib in China, 2010-2013

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Imatinib in China, 2010-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Imatinib Manufacturers in China, 2010-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Imatinib by Dosage Form in China, 2010-2013

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Imatinib Produced by Different Enterprises in China Hospital Market, 2014

  • 6.1. Novartis
  • 6.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • 6.3. Hansoh Pharmaceutical

7. Major Manufacturing Enterprises in China Imatinib Market, 2009-2014

  • 7.1. Novartis
  • 7.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • 7.3. Hansoh Pharmaceutical

8. Prospect of China Imatinib Market, 2014-2018

  • 8.1. Forecast on Incidence of CML
  • 8.2. Manufacturing Schedule of Generic Drug
  • 8.3. Forecast on Market Size
  • 8.4. Forecast on Competition Pattern

Selected Charts

  • Chart Imatinib Products Approved to Market in China, 2014
  • Chart Forecast on Market Size of Hospital-use Imatinib in China, 2014-2018
  • Chart Sales Value of Imatinib in Global Market, 2010-2013
  • Chart Sales Value of Imatinib in China Hospital Market, 2010-2013
  • Chart Sales Value of Imatinib by Region in China, 2010-2013
  • Chart Market Share of Imatinib Enterprises by Sales Value in China, 2010-2013
  • Chart Price of Imatinib Produced by Novartis in China Hospital Market, 2014
  • Chart Price of Imatinib Produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in China Hospital Market, 2014
Back to Top